Back to Awarded Treatment Trials
Awarded Trial: 02T-137
Grant ID
02T-137
Illness
Schizophrenia
Primary Drug/Intervention
Mirtazapine
Primary Dosage
30 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Cancelled
Investigator
Bertolino
Sample Size
30
Duration of Study Period for Each Subject
90 days
Outcome Measurements
PANSS, Cognitive battery
Results
Twenty-eight patients with schizophrenia were randomized to receive mirtazapine or placebo given adjunctively to olanzapine. There was a subtle benefit for the mirtazapine group on measures of negative symptoms. No differences in other symptom ratings or cognitive measures were detected.
Publication
N/A
Link
N/A
PI Name
Alessandro Bertolino
Degree
MD
Center
Clinica Psichiatrica II, Dipartimento di Scienze Neurologiche e Psichiatriche
Institution
Universita' degli Studi di Bari
Address
Piazza Giulio Cesare, 11
City or Town
Bari
State or Province
N/A
Zip or Postal Code
70124
Country
Italy
Email Address
bertolia@psichiat.uniba.it